Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Alnylam Pharmaceuticals : to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference

11/25/2020 | 08:02am EST

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 43rd Nasdaq Virtual Investor Conference on Friday, December 4, 2020 at 11:00 am ET.

A live audio webcast of the presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran). Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.


© Business Wire 2020
All news about ALNYLAM PHARMACEUTICALS, INC.
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/13ALNYLAM PHARMACEUTICALS : Cowen Adjusts Price Target on Alnylam Pharmaceuticals ..
MT
01/11ALNYLAM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
AQ
01/10ALNYLAM PHARMACEUTICALS : Launches “ P5x25” Strategy for Planned Tra..
BU
01/07ALNYLAM PHARMACEUTICALS : Says Late-Stage Study of Vutrisiran Meets Primary Endp..
MT
01/07ALNYLAM PHARMACEUTICALS : Reports Positive Topline Results from HELIOS-A Phase 3..
BU
01/04ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 39th Annual J.P. Morgan Hea..
BU
2020ALNYLAM PHARMACEUTICALS : UBS Adjusts Price Target on Alnylam Pharmaceuticals to..
MT
2020ALNYLAM PHARMACEUTICALS : Appoints Tolga Tanguler Chief Commercial Officer and A..
BU
2020ALNYLAM PHARMACEUTICALS : RBC Adjusts Alnylam Pharmaceuticals' Price Target to $..
MT
More news
Financials (USD)
Sales 2020 476 M - -
Net income 2020 -829 M - -
Net cash 2020 1 061 M - -
P/E ratio 2020 -24,3x
Yield 2020 -
Capitalization 20 027 M 20 027 M -
EV / Sales 2020 39,8x
EV / Sales 2021 24,0x
Nbr of Employees 1 323
Free-Float 99,2%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 165,33 $
Last Close Price 172,38 $
Spread / Highest target 30,5%
Spread / Average Target -4,09%
Spread / Lowest Target -47,8%
EPS Revisions
Managers and Directors
NameTitle
John M. Maraganore Chief Executive Officer & Director
Yvonne L. Greenstreet President & Chief Operating Officer
Michael W. Bonney Chairman
Jeffrey Poulton Chief Financial & Accounting Officer
Akshay K. Vaishnaw President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.32.63%20 027
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059